Metabolic surgery is a new term used to emphasize the metabolic benefits of a variety of bariatric surgery procedures, particularly with relationship to the treatment of type 2 diabetes and its complications. Means by which the likely impact of metabolic surgery on diabetes could be assessed in individual patients would be of clinical value.
Methods:
Two main scoring systems (ABCD and DiaRem) have been proposed to predict remission of diabetes after metabolic surgery. We present a description of these systems, discuss the sources of differences in their predictive power, and suggest means by which to improve predictive power.
Results:
ABCD is more predictive in patients with intermediate and poorer scores. Neither score is validated as a means of predicting, which patients will benefit most from the repercussions of improved glycemic control in terms of complications.
Conclusion:
A composite scoring system derived from ABCD and DiaRem may improve prediction of postoperative remission rates. Such a system should be considered principally as an aid to decision-making. Excessive focus on prediction of long-term remission of type 2 diabetes mellitus should be avoided in favor of identifying which patients may stand to benefit most, even if full clinical remission is not achieved.
Get full access to this article
View all access options for this article.
References
1.
XuY, WangL, HeJ, BiY, LiM, WangT, et al.Prevalence and control of diabetes in Chinese adults. JAMA, 2013; 310:948–959.
2.
BuseJB, CaprioS, CefaluWT, CerielloA, Del PratoS, InzucchiSE, et al.How do we define cure of diabetes?. Diabetes Care, 2009; 32:2133–2135.
3.
StrattonIM, AdlerAI, NeilHA, MatthewsDR, ManleySE, CullCA, et al.Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000; 321:405–412.
4.
YokoyamaH, OkudairaM, OtaniT, WatanabeC, TakaikeH, MiuiraJ, et al.High incidence of diabetic nephropathy in early-onset Japanese NIDDM patients. Risk analysis. Diabetes Care, 1998; 21:1080–1085.
5.
Al-RubeaanK, YoussefAM, IbrahimHM, Al-SharqawiAH, AlQumaidiH, AlNaqebD, et al.All-cause mortality and its risk factors among type 1 and type 2 diabetes mellitus in a country facing diabetes epidemic. Diabetes Res Clin Pract, 2016; 118:130–139.
6.
DixonJB. Obesity and diabetes: the impact of bariatric surgery on type-2 diabetes. World J Surg, 2009; 33:2014–2021.
7.
LeibsonCL, WilliamsonDF, MeltonLJ3rd, PalumboPJ, SmithSA, RansomJE, et al.Temporal trends in BMI among adults with diabetes. Diabetes Care, 2001; 24:1584–1589.
8.
FetnerR, McGintyJ, RussellC, Pi-SunyerFX, LaferrereB. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis, 2005; 1:589–597; discussion 597–598.
9.
HarteminkN, BoshuizenHC, NagelkerkeNJ, JacobsMA, van HouwelingenHC. Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. Am J Epidemiol, 2006; 163:1042–1052.
10.
ScopinaroN, MarinariGM, CameriniGB, PapadiaFS, AdamiGF. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care, 2005; 28:2406–2411.
11.
TejirianT, JensenC, DutsonE. Bariatric surgery and type 2 diabetes mellitus: surgically induced remission. J Diabetes Sci Technol, 2008; 2:685–691.
12.
DixonJB, O'BrienPE, PlayfairJ, ChapmanL, SchachterLM, SkinnerS, et al.Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA, 2008; 299:316–323.
13.
SchauerPR, BhattDL, KirwanJP, WolskiK, BrethauerSA, NavaneethanSD, et al.Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med, 2014; 370:2002–2013.
14.
SchauerPR, BhattDL, KirwanJP, WolskiK, AminianA, BrethauerSA, et al.Bariatric surgery versus intensive medical therapy for diabetes-5-year outcomes. N Engl J Med, 2017; 376:641–651.
15.
BuchwaldH, AvidorY, BraunwaldE, JensenMD, PoriesW, FahrbachK, et al.Bariatric surgery: a systematic review and meta-analysis. JAMA, 2004; 292:1724–1737.
16.
ArterburnDE, BogartA, SherwoodNE, SidneyS, ColemanKJ, HaneuseS, et al.A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg, 2013; 23:93–102.
17.
IkramuddinS, BillingtonCJ, LeeWJ, BantleJP, ThomasAJ, ConnettJE, et al.Roux-en-Y gastric bypass for diabetes (the Diabetes Surgery Study): 2-year outcomes of a 5-year, randomised, controlled trial. Lancet Diabetes Endocrinol, 2015; 3:413–422.
18.
MingroneG, PanunziS, De GaetanoA, GuidoneC, IaconelliA, NanniG, et al.Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, 2015; 386:964–973.
19.
RubinoF, NathanDM, EckelRH, SchauerPR, AlbertiKG, ZimmetPZ, et al.Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care, 2016; 39:861–877.
SmithBR, SchauerP, NguyenNT. Surgical approaches to the treatment of obesity: bariatric surgery. Med Clin North Am, 2011; 95:1009–1030.
22.
BuchwaldH, EstokR, FahrbachK, BanelD, JensenMD, PoriesWJ, et al.Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med, 2009; 122:248–256.e5.
23.
SjostromL, LindroosAK, PeltonenM, TorgersonJ, BouchardC, CarlssonB, et al.Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med, 2004; 351:2683–2693.
24.
JimenezA, CasamitjanaR, FloresL, ViaplanaJ, CorcellesR, LacyA, et al.Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg, 2012; 256:1023–1029.
25.
KaramanakosSN, VagenasK, KalfarentzosF, AlexandridesTK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg, 2008; 247:401–407.
26.
PeterliR, BorbelyY, KernB, GassM, PetersT, ThurnheerM, et al.Early results of the Swiss Multicentre Bypass or Sleeve Study (SM-BOSS): a prospective randomized trial comparing laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. Ann Surg, 2013; 258:690–694; discussion 695.
27.
MacDonaldKGJr., LongSD, SwansonMS, BrownBM, MorrisP, DohmGL, et al.The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg, 1997; 1:213–220; discussion 220.
28.
IaconelliA, PanunziS, De GaetanoA, MancoM, GuidoneC, LeccesiL, et al.Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up. Diabetes Care, 2011; 34:561–567.
29.
MirasAD, ChuahLL, KhalilN, NicotraA, VusirikalaA, BaqaiN, et al.Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case–control study. Diabetologia, 2015; 58:1443–1447.
30.
JohnsonBL, BlackhurstDW, LathamBB, CullDL, BourES, OliverTL, et al.Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg, 2013; 216:545–556; discussion 556–558.
31.
NavaneethanSD, KellyKR, SabbaghF, SchauerPR, KirwanJP, KashyapSR. Urinary albumin excretion, HMW adiponectin, and insulin sensitivity in type 2 diabetic patients undergoing bariatric surgery. Obes Surg, 2010; 20:308–315.
32.
HeneghanHM, CetinD, NavaneethanSD, OrzechN, BrethauerSA, SchauerPR. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis, 2013; 9:7–14.
33.
MirasAD, ChuahLL, LascaratosG, FaruqS, MohiteAA, ShahPR, et al.Bariatric surgery does not exacerbate and may be beneficial for the microvascular complications of type 2 diabetes. Diabetes Care, 2012; 35:e81.
34.
VaradhanL, HumphreysT, WalkerAB, CheruvuCV, VarugheseGI. Bariatric surgery and diabetic retinopathy: a pilot analysis. Obes Surg, 2012; 22:515–516.
35.
MirasAD, le RouxCW. Metabolic surgery: shifting the focus from glycaemia and weight to end-organ health. Lancet Diabetes Endocrinol, 2014; 2:141–151.
36.
LeeWJ, ChongK, ChenSC, ZachariahJ, SerKH, LeeYC, et al.Preoperative prediction of type 2 diabetes remission after gastric bypass surgery: a comparison of DiaRem scores and ABCD scores. Obes Surg, 2016; 26:2418–2424.
37.
LeeWJ, HurKY, LakadawalaM, KasamaK, WongSK, ChenSC, et al.Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis, 2013; 9:379–384.
38.
StillCD, WoodGC, BenottiP, PetrickAT, GabrielsenJ, StrodelWE, et al.Preoperative prediction of type 2 diabetes remission after Roux-en-Y gastric bypass surgery: a retrospective cohort study. Lancet Diabetes Endocrinol, 2014; 2:38–45.
39.
ZhangR, BorisenkoO, TeleginaI, HargreavesJ, AhmedAR, Sanchez SantosR, et al.Systematic review of risk prediction models for diabetes after bariatric surgery. Br J Surg, 2016; 103:1420–1427.
40.
LeeMH, LeeWJ, ChongK, ChenJC, SerKH, LeeYC, et al.Predictors of long-term diabetes remission after metabolic surgery. J Gastrointest Surg, 2015; 19:1015–1021.
41.
HayesMT, HuntLA, FooJ, TychinskayaY, StubbsRS. A model for predicting the resolution of type 2 diabetes in severely obese subjects following Roux-en Y gastric bypass surgery. Obes Surg, 2011; 21:910–916.
42.
StallardR, SahaiV, DroverJW, ChunS, KeresztesC. Defining and using preoperative predictors of diabetic remission following bariatric surgery. J Parenter Enteral Nutr, 2017 [Epub ahead of print]; DOI: 10.1177/0148607117697934.
43.
GuenziM, ArmanG, RauC, CordunC, MoszkowiczD, VoronT, et al.Remission of type 2 diabetes after omega loop gastric bypass for morbid obesity. Surg Endosc, 2015; 29:2669–2674.
44.
WangGF, YanYX, XuN, YinD, HuiY, ZhangJP, et al.Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg, 2015; 25:199–208.
45.
TharakanG, ScottR, SzepietowskiO, MirasAD, BlakemoreAI, PurkayasthaS, et al.Limitations of the DiaRem score in predicting remission of diabetes following Roux-En-Y gastric bypass (RYGB) in an ethnically diverse population from a single institution in the UK. Obes Surg, 2017; 27:782–786.
46.
TorquatiA, LutfiR, AbumradN, RichardsWO. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients?. J Gastrointest Surg, 2005; 9:1112–1116; discussion 1117–1118.
47.
VetterML, CardilloS, RickelsMR, IqbalN. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med, 2009; 150:94–103.
48.
VazquezG, DuvalS, JacobsDRJr., SilventoinenK. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. Epidemiol Rev, 2007; 29:115–128.
WilliamsonJR. Mechanism for the stimulation in vivo of hepatic gluconeogenesis by glucagon. Biochem J, 1966; 101:11c–14c.
51.
MingroneG, Castagneto-GisseyL. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab, 2009; 35(6 Pt 2):518–523.
52.
CamposJM, LinsDC, SilvaLB, Araujo-JuniorJG, ZeveJL, FerrazAA. Metabolic surgery, weight regain and diabetes re-emergence. Arq Bras Cir Dig, 2013; 26(Suppl 1):57–62.
53.
DiGiorgiM, RosenDJ, ChoiJJ, MiloneL, SchropeB, Olivero-RiveraL, et al.Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis, 2010; 6:249–253.
54.
LeeWJ, WangW, LeeYC, HuangMT, SerKH, ChenJC. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI >35 and <35 kg/m2. J Gastrointest Surg, 2008; 12:945–952.
55.
KularKS, ManchandaN, CheemaGK. Seven years of mini-gastric bypass in type II diabetes patients with a body mass index <35 kg/m(2). Obes Surg, 2016; 26:1457–1462.
56.
SjostromCD, LissnerL, WedelH, SjostromL. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS intervention study. Obes Res, 1999; 7:477–484.
57.
ParkJY, KimYJ. Prediction of diabetes remission in morbidly obese patients after Roux-en-Y gastric bypass. Obes Surg, 2016; 26:749–756.
58.
BhaskerAG, RemediosC, BatraP, SoodA, ShaikhS, LakdawalaM. Predictors of remission of T2DM and metabolic effects after laparoscopic Roux-en-y gastric bypass in obese indian diabetics-a 5-year study. Obes Surg, 2015; 25:1191–1197.
59.
NannipieriM, MariA, AnselminoM, BaldiS, BarsottiE, GuarinoD, et al.The role of beta-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab, 2011; 96:E1372–E1379.
60.
KimMK, LeeHC, KwonHS, BaekKH, KimEK, LeeKW, et al.Visceral obesity is a negative predictor of remission of diabetes 1 year after bariatric surgery. Obesity (Silver Spring), 2011; 19:1835–1839.
61.
YanH, TangL, ChenT, KralJG, JiangL, LiY, et al.Defining and predicting complete remission of type 2 diabetes: a short-term efficacy study of open gastric bypass. Obes Facts, 2013; 6:176–184.
62.
FlumDR, BelleSH, KingWC, WahedAS, BerkP, ChapmanW, et al.Perioperative safety in the longitudinal assessment of bariatric surgery. N Engl J Med, 2009; 361:445–454.
63.
PournarasDJ, le RouxCW. Can we predict diabetes remission after weight-loss surgery?. Lancet Diabetes Endocrinol, 2014; 2:4–6.
64.
SchauerPR, KashyapSR, WolskiK, BrethauerSA, KirwanJP, PothierCE, et al.Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med, 2012; 366:1567–1576.
65.
KimMK, LeeHC, LeeSH, KwonHS, BaekKH, KimEK, et al.The difference of glucostatic parameters according to the remission of diabetes after Roux-en-Y gastric bypass. Diabetes Metab Res Rev, 2012; 28:439–446.
66.
MayerSB, JeffreysAS, OlsenMK, McDuffieJR, FeinglosMN, YancyWSJr. Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes. Diabetes Obes Metab, 2014; 16:90–93.
67.
YancyWSJr., WestmanEC, McDuffieJR, GrambowSC, JeffreysAS, BoltonJ, et al.A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. Arch Int Med, 2010; 170:136–145.
68.
SchauerPR, BurgueraB, IkramuddinS, CottamD, GourashW, HamadG, et al.Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg, 2003; 238:467–484; discussion 484–485.
69.
LeeWJ, YuPJ, WangW, ChenTC, WeiPL, HuangMT. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg, 2005; 242:20–28.
70.
ChikunguwoSM, WolfeLG, DodsonP, MeadorJG, BaughN, CloreJN, et al.Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis, 2010; 6:254–259.
71.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2014; 37(Suppl 1):S81–S90.
72.
RaghowR. Bariatric surgery-mediated weight loss and its metabolic consequences for type-2 diabetes. World J Diabetes, 2013; 4:47–50.
73.
KhannaV, MalinSK, BenaJ, AboodB, PothierCE, BhattDL, et al.Adults with long-duration type 2 diabetes have blunted glycemic and beta-cell function improvements after bariatric surgery. Obesity (Silver Spring), 2015; 23:523–526.
74.
BrethauerSA, AminianA, Romero-TalamasH, BatayyahE, MackeyJ, KennedyL, et al.Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg, 2013; 258:628–636; discussion 636–637.
75.
DixonJB, O'BrienPE. Selecting the optimal patient for LAP-BAND placement. Am J Surg, 2002; 184(6B):17S–20S.
76.
HamzaN, AbbasMH, DarwishA, ShafeekZ, NewJ, AmmoriBJ. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis, 2011; 7:691–696.
77.
CarlssonLM, PeltonenM, AhlinS, AnvedenA, BouchardC, CarlssonB, et al.Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med, 2012; 367:695–704.
78.
Gletsu-MillerN, KahnHS, GasevicD, LiangZ, FredianiJK, TorresWE, et al.Sagittal abdominal diameter and visceral adiposity: correlates of beta-cell function and dysglycemia in severely obese women. Obes Surg, 2013; 23:874–881.
79.
LinE, PhillipsLS, ZieglerTR, SchmotzerB, WuK, GuLH, et al.Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes, 2007; 56:735–742.
80.
FainJN, MadanAK, HilerML, CheemaP, BahouthSW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology, 2004; 145:2273–2282.
81.
Van HarmelenV, ReynisdottirS, ErikssonP, ThorneA, HoffstedtJ, LonnqvistF, et al.Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes, 1998; 47:913–917.
82.
PouKM, MassaroJM, HoffmannU, LiebK, VasanRS, O'DonnellCJ, et al.Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care, 2009; 32:481–485.
83.
AbdelaalM, RouxCWl, DochertyNG. Surgical reduction of visceral versus subcutaneous fat and effect on features of the metabolic syndrome. Int Med Res Open J, 2016; 1:1–6.
84.
LimaMM, ParejaJC, AlegreSM, GelonezeSR, KahnSE, AstiarragaBD, et al.Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers. Obesity (Silver Spring), 2013; 21:E182–E189.
85.
GiuglianoG, NicolettiG, GrellaE, GiuglianoF, EspositoK, ScuderiN, et al.Effect of liposuction on insulin resistance and vascular inflammatory markers in obese women. Br J Plast Surg, 2004; 57:190–194.
